Physician profile
Stuart Felzer
NPI 1508804402
$5,873.68
in general payments reported to CMS, 2019-2025
32 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $829 · 2021: $1,413 · 2022: $924 · 2023: $562 · 2024: $745 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049 · Education: $65.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.12 |
| Education | $65.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $768.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $765.71 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $713.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $651.82 | 2019-2023 | |
| Astellas Pharma US INC | $536.74 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.66 | 2019-2025 | Jardiance |
| Abbvie INC. | $268.12 | 2019-2025 | |
| Glaxosmithkline, LLC. | $202.52 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $188.38 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $183.46 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $161.05 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $155.22 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.17 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $110.93 | 2019-2021 | |
| Abbott Laboratories | $109.13 | 2021-2025 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.30 | 2019-2025 | Repatha, Otezla, Evenity |
| Bausch Health US, LLC | $72.55 | 2021-2025 | Wellbutrin, Aplenzin |
| Allergan, INC. | $63.77 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $47.17 | 2025 | Austedo Xr |
| Eisai INC. | $43.22 | 2021 | |
| Tactile Systems Technology INC | $37.56 | 2024 | Entre Plus, Flexitouch Plus |
| Seqirus USA INC | $36.55 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $35.77 | 2019-2020 | |
| Antares Pharma, INC. | $25.84 | 2025 | Xyosted |
| Medtronic, INC. | $24.77 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.09 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.73 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $16.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.03 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $15.11 | 2020 | |
| Alfasigma USA, INC. | $12.58 | 2022 | |
| Sanofi Pasteur INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Felzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.